Yes, GPCRs are promising targets for cancer therapy due to their accessibility on the cell surface and their role in cancer-related signaling pathways. Several therapeutic strategies include:
GPCR Antagonists: Compounds that block GPCR activity can inhibit cancer cell proliferation and migration. For instance, antagonists targeting CXCR4 have shown potential in reducing metastasis. Monoclonal Antibodies: These can be designed to target specific GPCRs, preventing ligand binding and receptor activation. Biased Agonism: This approach selectively activates beneficial signaling pathways while avoiding harmful ones, potentially reducing side effects.
